|
|
Article: GlaxoSmithKline Plc (London UK) won approval of its Votrient as a treatment for patients with renal cell carcinoma, an advanced form of kidney cancer.(FDA ROUNDUP)
- Article from:
- MondayMorning
- Article date:
- October 26, 2009
CopyrightCOPYRIGHT 2009 MedContent Media, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Glaxo said about 57,700 people in the U.S. will be diagnosed with kidney cancer this year, and 13,000 people will die from the disease. The FDA said Votrient's side effects include diarrhea, high blood pressure, hair color changes, nausea, loss of appetite, vomiting, fatigue, weakness, abdominal pain and headache. The drug can also cause severe and fatal liver toxicity.
Elsewhere, French drugmaker Sanofi-Aventis SA received marketing clearance for its drug to help fight a serious complication of cancer treatment. The drug, Elitek, was approved for managing levels of plasma uric acid (PUA) that can build up as a side effect of cancer treatment, Sanofi said. High ...
Related newspaper, magazine, and journal articles:
|
|
Article: King Pharmaceuticals Receives FDA Approval ...
PR Newswire;
June 20, 2003 ;
700+ words
...King Pharmaceuticals, Inc. announced ... Administration ("FDA") approval of ... pleased to receive FDA approval of our ... not limited to, King Pharmaceuticals Research and Development ... dependence on FDA approval of the ...
|
|